Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.

October 16, 2017

Breastfeeding Lowers Infant’s Risk of Developing Bowel Disease Later, Study Reports

News

People who were breastfed are at lower risk of developing inflammatory bowel disease than those who weren’t, Massachusetts General Hospital researchers reported. The team said the protective effects applied to people across ... Read more

July 7, 2017August 29, 2017

IBD, Other Illnesses Shown to Delay Bowel Cancer Diagnosis

Crohn's Disease, News

The diagnosis of bowel cancer in patients with inflammatory bowel disease (IBD) and other serious illnesses is often significantly delayed compared to patients without pre-existing illness. This delayed diagnosis could ... Read more

June 19, 2017June 19, 2017

OSE Immunotherapeutics Says its IBD Candidate OSE-127 Could Help Treatment-resistant Patients

News

OSE Immunotherapeutics presented promising data from preclinical experiments of its investigational treatment OSE-127 (Effi-7) for inflammatory bowel disease (IBD) at FOCIS 2017, the Federation of Clinical Immunology Societies, held June 14-17 in ... Read more

June 14, 2017

More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says

News

More inflammatory bowel disease patients are switching biologic therapies than in 2016, according to a report by Spherix Global Insights RealWorld Dynamix. The appearance of Janssen’s Stelara (ustekinumab) — approved ... Read more

June 6, 2017June 6, 2017

Human, Mouse Studies Suggest MicroRNA Has Potential to Treat Crohn’s Disease, Ulcerative Colitis

News

Synthetic versions of a specific microRNA produced by white blood cells can reduce intestinal inflammation in mice, suggesting a new therapeutic approach to treating Crohn’s disease and ulcerative colitis, according ... Read more

May 31, 2017

Low Calcium, Vitamin D Intake Place IBD Kids at Risk for Poor Bone Health

News

The majority of children and adolescents with inflammatory bowel disease (IBD) do not get enough calcium and vitamin D through the diet, which jeopardizes their bone health and other issues ... Read more

May 22, 2017May 22, 2017

Switch From Remicade to Celltrion’s Biosimilar CT-P13 Safe in IBD, Clinical Trial Concludes

News

Patients with inflammatory bowel disease (IBD) may safely switch from Remicade (infliximab) to its biosimilar version CT-P13 — sold as Remsima and Inflectra — according to recently published clinical trial ... Read more

May 11, 2017

Zydus Wins Appeal in Shire’s Patent Case Over Generic Lialda for UC

News

Zydus Pharmaceuticals won a patent battle over Shire’s ulcerative colitis drug Lialda (mesalamine), with the U.S. Court of Appeals for the Federal Circuit ruling that Zydus’ proposed generic version of Lialda ... Read more

May 10, 2017

AbbVie’s Upadacitinib Benefits Crohn’s Patients in Phase 2 Trial, Supporting Advance to Phase 3

News

A Phase 2 trial (NCT02365649) of AbbVie’s investigational compound upadacitinib (ABT-494) showed the treatment had a positive effect in patients with Crohn’s disease, supporting the drug’s advance to Phase 3 ... Read more

April 20, 2017

Hospitalization Rates in Crohn’s Disease Suggest Patient Education Efforts Are Needed

News

Estimated hospitalization rates for Crohn’s disease have increased in the U.S., despite the introduction of treatments that researchers expected would improve remission and reduce hospitalizations. This led researchers to conclude that ... Read more